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Abstract Colchicine is a frequently used drug in
rheumatological diseases. Acute promyelocytic leukemia
developed in a patient who used colchicine for gouty
arthritis since 10 years is presented and the possible rela-
tion between the long term use of colchicine and hemato-
logical malignancies is discussed.
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Dear Editor,
Numerous factors, as individual genetic characteristics,
drugs and environmental factors, can affect cells to develop
malign process. It is known that autoimmune and chronic
inflammatory conditions can develop into malignant, leu-
kemia or lymphoproliferative diseases [1–3]. Ozdogu et al.
[1] were the first to describe an association between col-
chicine use and development of acute promyelocytic leu-
kemia (APL). They reported APL development upon long-
term use of colchicine to treat Behcet’s disease, and sug-
gested that a cytotoxic effect of the drug contributed to
chromosomal rearrangement associated with development
of leukemia. Gouty arthritis is another recurrent inflam-
matory disease caused by uric acid crystal deposition. In
this report, we describe a second case of APL in a patient
who had a history of long-term use of colchicine to treat
gouty arthritis.
A 44-year old male patient has suffered from of general
weakness and spontaneous ecchymosis present since
1 month. He has gouty arthritis for 15 years and coronary
heart disease for 5 years in his medical background. He
was receiving colchicine (Colchicum dispert, Dr F. Frig
Inc., Istanbul, Turkey) for the last 10 years, and clopido-
grel, metoprolol, acetylsalicylic acid for few years. On
physical examination multiple ecchymosis was detected.
The initial hemogram showed pancytopenia, coagulation
tests were in normal ranges except D-dimer (very high).
Bone marrow smear was revealed maturation arrest at
promyelocytic level with diminished erythroid elements.
Most of the cells contained abundant large granules and
Auer rods (Fig. 1). These cells were positive for CD13,
CD33, CD123, and negative for CD34 and HLA DR in the
immunophenotyping analysis. The conventional cytoge-
netic indicated t (15; 17) in all 20 metaphase cells.
Although due to lack of additional cytogenetic abnor-
malities, distinction of de novo or secondary leukemia
couldn’t be detected according to cytogenetic report.
The patient was diagnosed with APL. He was treated
AIDA protocol with supported blood and blood product if
necessary. Before initiation of maintenance therapy, the
patient achieved hematological and molecular remission.
Colchicine is often used to treat gout, gouty arthritis,
familial Mediterranean fever, and Behcet’s syndrome [1,
3]. The questions are: does an association exist between
development of APL and inflammatory disease or the as-
sociation is linked to chronicle use of colchicine? We know
& Nurhilal Buyukkurt
nurhilalt@yahoo.com
Asli Korur
aslipan@yahoo.com
Can Boga
drcanboga@hotmail.com
1 Department of Hematology, Baskent University Medical
Faculty, Ankara, Turkey
2 Adult Bone Marrow Transplantation Center Clinical Unit,
Baskent University Medical Faculty, Adana, Turkey
3 Present Address: Dadalog˘lu Mahallesi 2591 Sokak, No:4/A
01250 Yu¨reg˘ir, Adana, Turkey
123
Indian J Hematol Blood Transfus (June 2016) 32 (Suppl 1):S80–S81
DOI 10.1007/s12288-015-0523-4
that gouty arthritis is associated with increased risk of
cancer but the data shown this association with mostly
solid cancers [2]. Also the data from comprehensive
population based study shown association between au-
toimmune disease and acute myeloid leukemia (subtype
mostly APL), there is no data about gouty arthritis [3]. APL
is a particular subtype of AML often characterized by
particular cytogenetic abnormalities [1, 3]. The actions of
colchicine at the cellular level are not directly associated
with DNA modification, but genotoxic and mutagenic ef-
fects of colchicine on many cell types have been reported
[1, 5].
Colchicine is well-tolerated anti-inflammatory agent,
and finds wide application worldwide. In the USA, it ap-
pears that physicians diagnosing gouty arthritis prefer to
prescribe colchicine, to limit the use of corticosteroids and
non-steroidal anti-inflammatory drugs [4]. We wish to
suggest to the physician community that the possible
leukemogenic effect of colchicine should be considered in
every patient prescribed long-term colchicine therapy.
The inform consent was obtained from the patient for
being in this text.
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Fig. 1 Bone marrow smear is showing promyelocyte with Auer rods
(Wright–Giemsa staining, 1009 magnification)
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